Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
ASH 2018 - Chronic Lymphocytic Leukemia
ASH 2018 - Chronic Lymphocytic Leukemia
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of Patients with CLL with Mutated IGHV
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression-Free Survival Compared with Bendamustine plus Rituximab in Untreated Older Patients with CLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Results from the Phase 3 iLLUMINATE Study: Ibrutinib + Obinutuzumab as First-Line Treatment in Patients with CLL/SLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia: Updated Results from the Phase 1/2 ACE-CL-001 Study
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed/Refractory CLL
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
CLL Treatment Patterns, Dosing, and Sequencing: Interim Analysis Results from the Prospective informCLL Real-World Registry
Read More
ASH 2018 - Chronic Lymphocytic Leukemia
The Combination of Ibrutinib with Anti-CD19 CAR T-Cells Shows a High Response Rate in the Treatment of CLL
Read More
1
2
Page 2 of 2
Results 11 - 19 of 19